Last updated: February 10, 2026
Overview
Pemetrexed dipotassium is an antifolate chemotherapeutic agent approved primarily for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. It is marketed under brand names such as Alimta by Eli Lilly. The drug functions by inhibiting enzymes involved in folate-dependent pathways, thereby disrupting DNA synthesis in rapidly dividing cancer cells.
Market Size and Growth Trends
- Global lung cancer treatment market was valued at approximately USD 15 billion in 2022, with anticipation to reach USD 24 billion by 2030, growing at a CAGR of around 6%. Pemetrexed constitutes a significant share within this market.
- The NSCLC segment accounts for 60% of lung cancer cases, with pemetrexed used as a first-line therapy, especially for nonsquamous histology.
- The mesothelioma segment is smaller, with global incidence around 30,000 cases annually, mostly treated with pemetrexed plus cisplatin.
Patent and Market Exclusivity
- Original patent expired in the U.S. in 2017 but remains valid in various markets through patent extensions or orphan drug designations.
- Bio-similar competition remains limited due to complex manufacturing and regulatory hurdles; however, emerging biosimilar variants are in development, mostly targeting the non-U.S. markets.
- Eli Lilly retains market exclusivity through patents and regulatory exclusivities until 2025-2028 in key territories.
Regulatory and Developmental Landscape
- Pemetrexed's approvals include FDA (2004), EMA (2004), and other major health authorities.
- Ongoing research explores expanded indications, including combination therapies for head and neck cancers, triple-negative breast cancer, and indications in other solid tumors.
- Several Phase II and III trials are in progress or completed, examining efficacy, dosing, and combination strategies.
Competitive Position
| Competitor |
Drugs |
Market Share (2022) |
Key Features |
| Eli Lilly (Alimta) |
Pemetrexed dipotassium |
~70% |
First-mover advantage, established manufacturing scale |
| Biosimilar contenders |
Various biosimilars |
<10% in key markets |
Lower priced alternatives, limited approvals |
| Other chemotherapies |
Docetaxel, gemcitabine |
Remaining ~30% |
Used in various settings but less specific for NSCLC/pemetrexed indications |
Pricing & Reimbursement
- U.S. average wholesale price (AWP): USD 5,000–6,500 per 500 mg vial.
- Reimbursement policies favor pemetrexed due to extensive clinical data, though pricing pressure exists from biosimilar entrants.
Intellectual Property and Patent Challenges
- Patent expirations face increasing biosimilar development.
- Patent litigation and market exclusivity extensions may influence future pricing and market dynamics until around 2028.
Supply Chain & Manufacturing Considerations
- Complex synthesis process involving multiple steps.
- Eli Lilly owns manufacturing facilities with high-quality standards, maintaining supply stability.
- Potential investments in manufacturing capacity could improve margins amid rising demand.
Investment Risks
- Patent expiry and biosimilar entry could reduce margins.
- Pricing pressures driven by healthcare payers.
- Competition from emerging therapies, including immuno-oncology agents.
- Regulatory hurdles in non-U.S. markets.
Future Outlook
- Continued growth driven by first-line NSCLC treatment and expanding indications.
- Likelihood of sustained revenue through ongoing patent protections and new clinical data.
- Opportunities exist in developing combination regimens and exploring new indications.
- Risks from biosimilar competition and pricing negotiations.
Key Takeaways
- Pemetrexed dipotassium remains a core treatment in NSCLC and mesothelioma with a solid market presence.
- Patent expirations and biosimilar entry pose long-term risks but are offset by brand recognition and established clinical use.
- The global market growth relies heavily on regulatory approval and expanding indications.
- Competitive landscape shifts under biosimilar development may impact future pricing.
- Investment strategies should consider patent timelines, pipeline developments, and manufacturing stability.
FAQs
-
When do key patents for pemetrexed dipotassium expire?
Major patents are expected to expire around 2025–2028 in the U.S. and Europe, opening markets for biosimilar competition.
-
What are the primary clinical indications for pemetrexed?
It is approved for nonsquamous non-small cell lung cancer, malignant pleural mesothelioma, and off-label in other solid tumors.
-
How competitive is the market for pemetrexed?
Dominated by Eli Lilly, with biosimilar entrants in development, especially outside the U.S., where patent protections are weaker.
-
What are the main risks for investors?
Patent expiry, biosimilar competition, pricing pressure, and potential regulatory changes.
-
What is the outlook for future growth?
The outlook remains positive due to expanding indications and ongoing clinical trials; however, growth may decline post-patent expiration unless new formulations or indications emerge.
Sources
[1] MarketsandMarkets, "Lung Cancer Therapeutics Market," 2023.
[2] Eli Lilly, "Alimta Product Information," 2022.
[3] FDA, "Pemetrexed (Alimta) Approval," 2004.
[4] ClinicalTrials.gov, "Pemetrexed Trials," 2023.
[5] IQVIA, "Global Oncology Market Data," 2022.
